comparemela.com

Latest Breaking News On - Janssen cilag gm - Page 1 : comparemela.com

Janssen Announces Erdafitinib Improved Overall Survival

Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with.

France generalRegion flamandeUnited statesMilenkovic petronicSipetic grujicics urothelialJanssen cilag gmYohann loriotKiran patelInstitut gustave roussyJanssen pharmaceuticaClinical developmentCompanies of johnsonAstex therapeuticsDrug administrationJanssen pharmaceutical companiesJanssen research development in phase

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®. | April 21, 2023

Region flamandeUnited kingdomCity ofJanssen cilag gmbMartin vogelMagda palhotaPeter lebowitzGerhardt attardJanssen cilag gmUrology care foundationExchange commissionDrug administrationCompanies of johnsonJanssen research developmentEuropean medicines agencyUniversity college london

Janssen: New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM? (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis

Early treatment in multiple sclerosis (MS) with higher-potency therapies can improve long-term patient outcomes1,2 New subgroup analysis of the pivotal Phase 3 OPTIMUM trial shows that MS patients

Janssen cilag gmAlexandra nisipeanuJennifer mcintyrePrinzj ponesimodJanssen cilag internationalNone of the janssen pharmaceutical companiesEuropean commissionNational multiple sclerosis societyJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonActelion pharmaceuticals ltdExchange commissionJanssen global servicesCompanies of johnsonIdorsia pharmaceuticals ltdEuropean committee

vimarsana © 2020. All Rights Reserved.